Introduction: Group B Streptococcus (GBS) positive patients with penicillin allergies receive intrapartum antibiotics for neonatal sepsis prophylaxis based on recommendations from the American College of Obstetricians and Gynecologists (ACOG). The objective of this study was to determine which antibiotics are used in GBS positive patients with documented penicillin allergies and evaluate for antibiotic stewardship improvements at a tertiary hospital in the Midwestern U.S.
Methods: Retrospective chart review identified GBS positive patients with and without penicillin allergies admitted to the labor and delivery floor. EMR-documented penicillin allergy severity, results of antibiotic susceptibility testing, and all antibiotics administered from admission to delivery were recorded. The study population was divided based on penicillin allergy status with antibiotic choice analyzed using Fisher's exact test.
Results: 406 GBS positive patients underwent labor between May 1, 2019, and April 30, 2020. Penicillin allergy was documented in 62 (15.3 percent) patients. Of these patients, cefazolin and vancomycin were prescribed most frequently for intrapartum neonatal sepsis prophylaxis. Antibiotic susceptibility testing was performed on the GBS isolate in 74.2 percent of the penicillin allergic patients. Between penicillin allergy and no penicillin allergy groups, the frequency of ampicillin, cefazolin, clindamycin, gentamicin, and vancomycin use showed statistical differences.
Conclusion: The study results suggest that antibiotic choice for neonatal sepsis prophylaxis in GBS positive patients with penicillin allergy at a tertiary Midwestern hospital follows current ACOG guidelines. Cefazolin was used most frequently in this population followed by vancomycin and clindamycin. Our results identify room for improvement regarding regular antibiotic susceptibility testing in GBS positive patients with penicillin allergy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Successful removal of penicillin allergy label in a tertiary hospital in Paraguay].
Rev Alerg Mex
December 2024
Jefe del servicio de Alergia, Hospital Central del Instituto de Previsión Social (IPS), Paraguay.
Objective: To develop a treatment algorithm for patients with penicillin allergy.
Methods: Retrospective study, carried out in adult patients with penicillin allergy, who were in group 3 or 4 of the established classification, and attended the outpatient clinic of the Department of Pulmonology and Allergy of the Central Hospital of the Social Security Institute, between January 2021 and December 2022. Each patient underwent an amoxicillin provocation test, after obtaining informed consent.
Penicillin allergy management strategies relevant for clinical practice - a narrative review.
Rom J Intern Med
January 2025
2IDESP, University of Montpellier-INSERM, Montpellier, France, 34093.
Penicillin allergy is the most commonly reported drug allergy, with prevalence rates ranging from 6% to 31% across various populations and geographic areas. The penicillin allergy label is linked to higher mortality and morbidity rates, extended hospital stays, increased readmission rates, and a greater reliance on second-line antibiotics. Research indicates that nearly 99% of those labeled as penicillin-allergic can tolerate the drug.
View Article and Find Full Text PDFHealth disparities investigated in a primary care penicillin allergy removal pathway.
Allergy Asthma Proc
January 2025
Division of Pediatric Medicine, Naval Medical Center Portsmouth, Portsmouth, Virginia.
Unconfirmed penicillin allergies over time lead to poor health outcomes and increased health-care cost. Health disparities (HD) can create barriers in optimizing penicillin allergy care. The objective was to characterize HDs in our primary care-led amoxicillin challenge (PLAC) delabeling pathway within a universal coverage health care system.
View Article and Find Full Text PDFNon-Allergist Delabeling - Should penicillin allergy delabeling only be performed by allergists?
J Allergy Clin Immunol Pract
December 2024
Centre for Antibiotic Allergy and Research, Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia; Division of Allergy and Clinical Immunology, Department of Medicine, McGill University Health Centre (MUHC), McGill University, Montreal, Quebec, Canada; The Research Institute of the McGill University Health Centre, McGill University, McGill University Health Centre (MUHC), Montreal, Quebec, Canada.
Penicillin allergy labels (PAL) are common but rarely correspond with a patient's likelihood to tolerate penicillin. This results in unnecessary penicillin avoidance in many patients, driving numerous negative health outcomes. Evaluation strategies for PAL are driven by risk stratification and include a spectrum of modalities such as delabeling without any testing, direct oral challenge, and skin testing followed by challenge testing.
View Article and Find Full Text PDFSymmetrical Drug-Related Intertriginous and Flexural Exanthema With Amoxicillin: Presenting a Flare-Up Phenomenon.
Cureus
November 2024
Allergy Department, Hospital General Universitario Gregorio Marañón, Madrid, ESP.
This case report describes a 40-year-old male patient who developed symmetrical drug-related intertriginous and flexural exanthema after taking amoxicillin. Initial allergy testing showed negative intradermal tests, but subsequent drug provocation tests with amoxicillin and penicillin were positive, indicating cross-reactivity between these β-lactam antibiotics. Notably, following the final provocation test, the intradermal test with penicillin turned positive, demonstrating a flare-up phenomenon.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!